

# Arnon Nagler

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/2760188/arnon-nagler-publications-by-citations.pdf>

**Version:** 2024-04-17

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

333  
papers

16,352  
citations

62  
h-index

117  
g-index

366  
ext. papers

19,477  
ext. citations

6.1  
avg, IF

6.14  
L-index

#	Paper	IF	Citations
333	Nonmyeloablative Stem Cell Transplantation and Cell Therapy as an Alternative to Conventional Bone Marrow Transplantation With Lethal Cytoablation for the Treatment of Malignant and Nonmalignant Hematologic Diseases. <i>Blood</i> , <b>1998</b> , 91, 756-763	2.2	1780
332	Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. <i>Clinical Cancer Research</i> , <b>2008</b> , 14, 3044-51	12.9	563
331	CD44 and hyaluronic acid cooperate with SDF-1 in the trafficking of human CD34+ stem/progenitor cells to bone marrow. <i>Blood</i> , <b>2004</b> , 103, 2981-9	2.2	436
330	Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukemia Working Party (ALWP) of the European Group for Blood and Marrow Transplantation (EBMT). <i>Leukemia</i> , <b>2005</b> , 19, 2014-22	10.7	380
329	Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia: a retrospective risk factors analysis and comparison with other strategies by the EBMT Acute Leukemia Working Party. <i>Journal of Clinical Oncology</i> , <b>2007</b> , 25, 4938-45	2.2	357
328	Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation. <i>Blood</i> , <b>1996</b> , 87, 2195-2204	2.2	354
327	Antilymphocyte Globulin for Prevention of Chronic Graft-versus-Host Disease. <i>New England Journal of Medicine</i> , <b>2016</b> , 374, 43-53	59.2	321
326	Related umbilical cord blood transplantation in patients with thalassemia and sickle cell disease. <i>Blood</i> , <b>2003</b> , 101, 2137-43	2.2	315
325	Hematopoietic stem cell transplantation in Europe 2014: more than 40 000 transplants annually. <i>Bone Marrow Transplantation</i> , <b>2016</b> , 51, 786-92	4.4	265
324	Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: the role of dose intensity. <i>Leukemia</i> , <b>2006</b> , 20, 322-8	10.7	257
323	A survey of fully haploidentical hematopoietic stem cell transplantation in adults with high-risk acute leukemia: a risk factor analysis of outcomes for patients in remission at transplantation. <i>Blood</i> , <b>2008</b> , 112, 3574-81	2.2	242
322	Use of haploidentical stem cell transplantation continues to increase: the 2015 European Society for Blood and Marrow Transplant activity survey report. <i>Bone Marrow Transplantation</i> , <b>2017</b> , 52, 811-817	4.4	235
321	Transplantation of mobilized peripheral blood cells to HLA-identical siblings with standard-risk leukemia. <i>Blood</i> , <b>2002</b> , 100, 761-7	2.2	228
320	Indications for allo- and auto-SCT for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2015. <i>Bone Marrow Transplantation</i> , <b>2015</b> , 50, 1037-56	4.4	226
319	Revised diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a new classification from the European Society for Blood and Marrow Transplantation. <i>Bone Marrow Transplantation</i> , <b>2016</b> , 51, 906-12	4.4	224
318	Sinusoidal obstruction syndrome/veno-occlusive disease: current situation and perspectives-a position statement from the European Society for Blood and Marrow Transplantation (EBMT). <i>Bone Marrow Transplantation</i> , <b>2015</b> , 50, 781-9	4.4	217
317	Transplantation of ex vivo expanded cord blood cells using the copper chelator tetraethylenepentamine: a phase I/II clinical trial. <i>Bone Marrow Transplantation</i> , <b>2008</b> , 41, 771-8	4.4	203

316	Allogeneic bone marrow transplantation vs filgrastim-mobilised peripheral blood progenitor cell transplantation in patients with early leukaemia: first results of a randomised multicentre trial of the European Group for Blood and Marrow Transplantation. <i>Bone Marrow Transplantation</i> , <b>1998</b> , 21, 995-1003	4.4	202
315	Treatment, risk factors, and outcome of adults with relapsed AML after reduced intensity conditioning for allogeneic stem cell transplantation. <i>Blood</i> , <b>2012</b> , 119, 1599-606	2.2	191
314	Prophylaxis and treatment of GVHD: EBMT-ELN working group recommendations for a standardized practice. <i>Bone Marrow Transplantation</i> , <b>2014</b> , 49, 168-73	4.4	181
313	Haploidentical, unmanipulated, G-CSF-primed bone marrow transplantation for patients with high-risk hematologic malignancies. <i>Blood</i> , <b>2013</b> , 121, 849-57	2.2	179
312	Comparison of outcomes after unrelated cord blood and unmanipulated haploidentical stem cell transplantation in adults with acute leukemia. <i>Leukemia</i> , <b>2015</b> , 29, 1891-900	10.7	158
311	Hematopoietic SCT in Europe 2013: recent trends in the use of alternative donors showing more haploidentical donors but fewer cord blood transplants. <i>Bone Marrow Transplantation</i> , <b>2015</b> , 50, 476-82	4.4	151
310	Allogeneic peripheral blood stem cell transplantation using a fludarabine-based low intensity conditioning regimen for malignant lymphoma. <i>Bone Marrow Transplantation</i> , <b>2000</b> , 25, 1021-8	4.4	148
309	Definition of GvHD-free, relapse-free survival for registry-based studies: an ALWP-EBMT analysis on patients with AML in remission. <i>Bone Marrow Transplantation</i> , <b>2016</b> , 51, 610-1	4.4	144
308	Outcomes of reduced-intensity transplantation for chronic myeloid leukemia: an analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMT. <i>Blood</i> , <b>2005</b> , 106, 2969-76	2.2	142
307	Impact of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation for acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European group for blood and marrow transplantation. <i>Leukemia</i> , <b>2012</b> , 26, 2462-8	10.7	133
306	Indications for haematopoietic stem cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2019. <i>Bone Marrow Transplantation</i> , <b>2019</b> , 54, 1525-1552	4.4	128
305	Umbilical cord blood transplantation--how, when and for whom?. <i>Blood Reviews</i> , <b>2004</b> , 18, 167-79	11.1	122
304	Allogeneic hematopoietic stem-cell transplantation for acute myeloid leukemia in remission: comparison of intravenous busulfan plus cyclophosphamide (Cy) versus total-body irradiation plus Cy as conditioning regimen--a report from the acute leukemia working party of the European group for blood and marrow transplantation. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 3549-56	2.2	116
303	Halofuginone to prevent and treat thioacetamide-induced liver fibrosis in rats. <i>Hepatology</i> , <b>2001</b> , 33, 379-86	11.2	109
302	Relapse of AML after hematopoietic stem cell transplantation: methods of monitoring and preventive strategies. A review from the ALWP of the EBMT. <i>Bone Marrow Transplantation</i> , <b>2016</b> , 51, 1431-1438	4.4	106
301	Linear polyamine copper chelator tetraethylenepentamine augments long-term ex vivo expansion of cord blood-derived CD34+ cells and increases their engraftment potential in NOD/SCID mice. <i>Experimental Hematology</i> , <b>2004</b> , 32, 547-55	3.1	105
300	Autologous haematopoietic stem cell mobilisation in multiple myeloma and lymphoma patients: a position statement from the European Group for Blood and Marrow Transplantation. <i>Bone Marrow Transplantation</i> , <b>2014</b> , 49, 865-72	4.4	104
299	Busulfan plus cyclophosphamide versus busulfan plus fludarabine as a preparative regimen for allogeneic haemopoietic stem-cell transplantation in patients with acute myeloid leukaemia: an open-label, multicentre, randomised, phase 3 trial. <i>Lancet Oncology</i> , <b>2015</b> , 16, 1525-1536	21.7	103

298	Multiple myeloma cells recruit tumor-supportive macrophages through the CXCR4/CXCL12 axis and promote their polarization toward the M2 phenotype. <i>Oncotarget</i> , <b>2014</b> , 5, 11283-96	3.3	99
297	Tyrosine kinase inhibitors improve long-term outcome of allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia. <i>Haematologica</i> , <b>2015</b> , 100, 392-9	6.6	97
296	Use of tyrosine kinase inhibitors to prevent relapse after allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A position statement of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Cancer</i> , <b>2016</b> , 122, 2941-51	6.4	97
295	Low-intensity conditioning is sufficient to ensure engraftment in matched unrelated bone marrow transplantation. <i>Experimental Hematology</i> , <b>2001</b> , 29, 362-70	3.1	89
294	Halofuginone: a potent inhibitor of critical steps in angiogenesis progression. <i>FASEB Journal</i> , <b>2000</b> , 14, 2477-85	0.9	88
293	Comparison between two fludarabine-based reduced-intensity conditioning regimens before allogeneic hematopoietic stem-cell transplantation: fludarabine/melphalan is associated with higher incidence of acute graft-versus-host disease and non-relapse mortality and lower incidence	10.7	85
292	Prediction of Allogeneic Hematopoietic Stem-Cell Transplantation Mortality 100 Days After Transplantation Using a Machine Learning Algorithm: A European Group for Blood and Marrow Transplantation Acute Leukemia Working Party Retrospective Data Mining Study. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 3144-51	2.2	83
291	Post-transplant cyclophosphamide versus anti-thymocyte globulin as graft-versus-host disease prophylaxis in haploidentical transplant. <i>Haematologica</i> , <b>2017</b> , 102, 401-410	6.6	82
290	Impact of in vivo T-cell depletion on outcome of AML patients in first CR given peripheral blood stem cells and reduced-intensity conditioning allo-SCT from a HLA-identical sibling donor: a report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. <i>Bone Marrow Transplantation</i> , <b>2014</b> , 49, 389-96	4.4	82
289	A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS). <i>Leukemia</i> , <b>2017</b> , 31, 107-114	10.7	81
288	The effect of prior exposure to imatinib on transplant-related mortality. <i>Haematologica</i> , <b>2006</b> , 91, 452-966		79
287	Bone marrow versus mobilized peripheral blood stem cells in haploidentical transplants using posttransplantation cyclophosphamide. <i>Cancer</i> , <b>2018</b> , 124, 1428-1437	6.4	78
286	Hematopoietic stem-cell transplantation from unrelated donors in elderly patients (age >55 years) with hematologic malignancies: older age is no longer a contraindication when using reduced intensity conditioning. <i>Leukemia</i> , <b>2005</b> , 19, 7-12	10.7	77
285	Immunotherapy With Recombinant Human Interleukin-2 and Recombinant Interferon- $\gamma$ in Lymphoma Patients Postautologous Marrow or Stem Cell Transplantation. <i>Blood</i> , <b>1997</b> , 89, 3951-3959	2.2	73
284	Reduced-toxicity conditioning with treosulfan, fludarabine and ATG as preparative regimen for allogeneic stem cell transplantation (alloSCT) in elderly patients with secondary acute myeloid leukemia (SAML) or myelodysplastic syndrome (MDS). <i>Bone Marrow Transplantation</i> , <b>2006</b> , 37, 339-44	4.4	73
283	Cellular copper content modulates differentiation and self-renewal in cultures of cord blood-derived CD34+ cells. <i>British Journal of Haematology</i> , <b>2002</b> , 116, 655-61	4.5	72
282	Outcomes of allogeneic haematopoietic stem cell transplantation from HLA-matched and alternative donors: a European Society for Blood and Marrow Transplantation registry retrospective analysis. <i>Lancet Haematology</i> , <b>2019</b> , 6, e573-e584	14.6	71
281	Outcome of patients with distinct molecular genotypes and cytogenetically normal AML after allogeneic transplantation. <i>Blood</i> , <b>2015</b> , 126, 2062-9	2.2	71

280	Use of Chimeric Antigen Receptor T Cell Therapy in Clinical Practice for Relapsed/Refractory Aggressive B Cell Non-Hodgkin Lymphoma: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy. <i>Biology of Blood and Marrow Transplantation</i> , <b>2019</b> , 25, 2305-2321	4.7	68
279	Rituximab reduces relapse risk after allogeneic and autologous stem cell transplantation in patients with high-risk aggressive non-Hodgkin's lymphoma. <i>British Journal of Haematology</i> , <b>2003</b> , 122, 457-64	4.5	68
278	Hematopoietic stem cell transplantation for adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first remission: a position statement of the European Working Group for Adult Acute Lymphoblastic Leukemia (EWALL) and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT). <i>Bone Marrow Transplantation</i> , <b>2019</b> , 54, 758-809	4.4	68
277	Improving results of allogeneic hematopoietic cell transplantation for adults with acute lymphoblastic leukemia in first complete remission: an analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Haematologica</i> , <b>2017</b> , 102, 139-149	6.6	65
276	Heparanase enhances myeloma progression via CXCL10 downregulation. <i>Leukemia</i> , <b>2014</b> , 28, 2178-87	10.7	65
275	Posttransplant cyclophosphamide vs antithymocyte globulin in HLA-mismatched unrelated donor transplantation. <i>Blood</i> , <b>2019</b> , 134, 892-899	2.2	64
274	Treosulfan-based conditioning before hematopoietic SCT: more than a BU look-alike. <i>Bone Marrow Transplantation</i> , <b>2012</b> , 47, 5-14	4.4	63
273	Is there a stronger graft-versus-leukemia effect using HLA-haploidentical donors compared with HLA-identical siblings?. <i>Leukemia</i> , <b>2016</b> , 30, 447-55	10.7	62
272	A comparison between allogeneic stem cell transplantation from unmanipulated haploidentical and unrelated donors in acute leukemia. <i>Journal of Hematology and Oncology</i> , <b>2017</b> , 10, 24	22.4	62
271	Reduced intensity conditioning allogeneic hematopoietic cell transplantation for adult acute myeloid leukemia in complete remission - a review from the Acute Leukemia Working Party of the EBMT. <i>Haematologica</i> , <b>2015</b> , 100, 859-69	6.6	62
270	Application of machine learning algorithms for clinical predictive modeling: a data-mining approach in SCT. <i>Bone Marrow Transplantation</i> , <b>2014</b> , 49, 332-7	4.4	62
269	Anti-thymocyte globulin as graft-versus-host disease prevention in the setting of allogeneic peripheral blood stem cell transplantation: a review from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Haematologica</i> , <b>2017</b> , 102, 224-234	6.6	61
268	Locally produced CD19 CAR T cells leading to clinical remissions in medullary and extramedullary relapsed acute lymphoblastic leukemia. <i>American Journal of Hematology</i> , <b>2018</b> , 93, 1485-1492	7.1	61
267	The CXCR4 inhibitor BL-8040 induces the apoptosis of AML blasts by downregulating ERK, BCL-2, MCL-1 and cyclin-D1 via altered miR-15a/16-1 expression. <i>Leukemia</i> , <b>2017</b> , 31, 2336-2346	10.7	59
266	Outcome of patients with HTLV-1-associated adult T-cell leukemia/lymphoma after SCT: a retrospective study by the EBMT LWP. <i>Bone Marrow Transplantation</i> , <b>2014</b> , 49, 1266-8	4.4	59
265	Factors affecting mortality following myeloablative cord blood transplantation in adults: a pooled analysis of three international registries. <i>Bone Marrow Transplantation</i> , <b>2011</b> , 46, 70-6	4.4	59
264	Alternative donors for allogeneic hematopoietic stem cell transplantation in poor-risk AML in CR1. <i>Blood Advances</i> , <b>2017</b> , 1, 477-485	7.8	57
263	Reduced-intensity conditioning with fludarabine and busulfan versus fludarabine and melphalan for patients with acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. <i>Cancer</i> , <b>2015</b> , 121, 1048-55	6.4	56

262	Prediction of non-relapse mortality in recipients of reduced intensity conditioning allogeneic stem cell transplantation with AML in first complete remission. <i>Leukemia</i> , <b>2015</b> , 29, 51-7	10.7	55
261	Combination of imatinib with CXCR4 antagonist BKT140 overcomes the protective effect of stroma and targets CML in vitro and in vivo. <i>Molecular Cancer Therapeutics</i> , <b>2014</b> , 13, 1155-69	6.1	55
260	Growth inhibition of prostate cancer xenografts by halofuginone. <i>Prostate</i> , <b>2002</b> , 51, 73-83	4.2	55
259	Measurable residual disease, conditioning regimen intensity, and age predict outcome of allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first remission: A registry analysis of 2292 patients by the Acute Leukemia Working Party European Society of Blood and Marrow Transplantation. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 1428-1435	7.1	54
258	Outcomes of hematopoietic stem cell transplantation from unmanipulated haploidentical versus matched sibling donor in patients with acute myeloid leukemia in first complete remission with intermediate or high-risk cytogenetics: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Haematologica</i> , <b>2018</b> , 103, 1317-1328	6.6	54
257	Filgrastim-mobilized peripheral blood progenitor cells versus bone marrow transplantation for treating leukemia: 3-year results from the EBMT randomized trial. <i>Haematologica</i> , <b>2005</b> , 90, 643-8	6.6	54
256	Association of Second Allogeneic Hematopoietic Cell Transplant vs Donor Lymphocyte Infusion With Overall Survival in Patients With Acute Myeloid Leukemia Relapse. <i>JAMA Oncology</i> , <b>2018</b> , 4, 1245-1253	13.4	53
255	A phase 2 study of MK-0457 in patients with BCR-ABL T315I mutant chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia. <i>Blood Cancer Journal</i> , <b>2014</b> , 4, e238	7	53
254	Reduced-intensity conditioning allogeneic stem cell transplantation for relapsed/refractory mantle cell lymphoma: a multicenter experience. <i>Annals of Oncology</i> , <b>2012</b> , 23, 2695-2703	10.3	51
253	Haploidentical hematopoietic cell transplantation for adult acute myeloid leukemia: a position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Haematologica</i> , <b>2017</b> , 102, 1810-1822	6.6	49
252	Targeting the CD20 and CXCR4 pathways in non-hodgkin lymphoma with rituximab and high-affinity CXCR4 antagonist BKT140. <i>Clinical Cancer Research</i> , <b>2013</b> , 19, 3495-507	12.9	48
251	Unmanipulated haploidentical stem cell transplantation in adults with acute lymphoblastic leukemia: a study on behalf of the Acute Leukemia Working Party of the EBMT. <i>Journal of Hematology and Oncology</i> , <b>2017</b> , 10, 113	22.4	48
250	A survey on unmanipulated haploidentical hematopoietic stem cell transplantation in adults with acute leukemia. <i>Leukemia</i> , <b>2015</b> , 29, 1069-75	10.7	46
249	Extreme heterogeneity of myeloablative total body irradiation techniques in clinical practice: a survey of the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. <i>Cancer</i> , <b>2014</b> , 120, 2760-5	6.4	46
248	Mobilized peripheral blood stem cells compared with bone marrow as the stem cell source for unrelated donor allogeneic transplantation with reduced-intensity conditioning in patients with acute myeloid leukemia in complete remission: an analysis from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , <b>2012</b> , 18, 1472-9	4.7	46
247	The European Society for Blood and Marrow Transplantation (EBMT) consensus recommendations for donor selection in haploidentical hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , <b>2020</b> , 55, 12-24	4.4	46
246	Mobilized peripheral blood grafts include more than hematopoietic stem cells: the immunological perspective. <i>Bone Marrow Transplantation</i> , <b>2015</b> , 50, 886-91	4.4	45
245	Impact of conditioning intensity in T-replete haplo-identical stem cell transplantation for acute leukemia: a report from the acute leukemia working party of the EBMT. <i>Journal of Hematology and Oncology</i> , <b>2016</b> , 9, 25	22.4	44

244	Fludarabine-based protocol for human umbilical cord blood transplantation in children with Fanconi anemia. <i>Journal of Pediatric Hematology/Oncology</i> , <b>1999</b> , 21, 237-9	1.2	43
243	Genetic variations in the heparanase gene (HPSE) associate with increased risk of GVHD following allogeneic stem cell transplantation: effect of discrepancy between recipients and donors. <i>Blood</i> , <b>2010</b> , 115, 2319-28	2.2	42
242	Allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning in patients with refractory and recurrent multiple myeloma: long-term follow-up. <i>Cancer</i> , <b>2010</b> , 116, 3621-30	6.4	42
241	Suppression of hepatocellular carcinoma growth in mice by the alkaloid coccidiostat halofuginone. <i>European Journal of Cancer</i> , <b>2004</b> , 40, 1397-403	7.5	42
240	Optimizing the conditioning regimen for allogeneic stem-cell transplantation in acute myeloid leukemia; dose intensity is still in need. <i>Best Practice and Research in Clinical Haematology</i> , <b>2011</b> , 24, 369-79	4.3	41
239	Postpartum umbilical cord blood collection for transplantation: a comparison of three methods. <i>American Journal of Obstetrics and Gynecology</i> , <b>2000</b> , 182, 227-32	6.4	41
238	Ex vivo expansion of CD56+ cytotoxic cells from human umbilical cord blood. <i>Experimental Hematology</i> , <b>2001</b> , 29, 104-13	3.1	40
237	High CD3+ and CD34+ peripheral blood stem cell grafts content is associated with increased risk of graft-versus-host disease without beneficial effect on disease control after reduced-intensity conditioning allogeneic transplantation from matched unrelated donors for acute myeloid leukemia. <i>Journal of Clinical Investigation</i> , <b>2011</b> , 121, 103-11	3.3	40
236	Hematopoietic Cell Transplantation in the Treatment of Adult Acute Lymphoblastic Leukemia: Updated 2019 Evidence-Based Review from the American Society for Transplantation and Cellular Therapy. <i>Biology of Blood and Marrow Transplantation</i> , <b>2019</b> , 25, 2113-2123	4.7	38
235	Association of heparanase gene (HPSE) single nucleotide polymorphisms with hematological malignancies. <i>Leukemia</i> , <b>2007</b> , 21, 2296-303	10.7	38
234	Phase 1/2 study of nilotinib prophylaxis after allogeneic stem cell transplantation in patients with advanced chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia. <i>Cancer</i> , <b>2015</b> , 121, 863-71	6.4	37
233	Impact of conditioning with TBI in adult patients with T-cell ALL who receive a myeloablative allogeneic stem cell transplantation: a report from the acute leukemia working party of EBMT. <i>Bone Marrow Transplantation</i> , <b>2016</b> , 51, 351-7	4.4	37
232	Prior treatment with the tyrosine kinase inhibitors dasatinib and nilotinib allows stem cell transplantation (SCT) in a less advanced disease phase and does not increase SCT Toxicity in patients with chronic myelogenous leukemia and philadelphia positive acute lymphoblastic leukemia. <i>Leukemia</i> , <b>2009</b> , 23, 190-4	10.7	37
231	Ibritumomab tiuxetan (Zevalin) combined with reduced-intensity conditioning and allogeneic stem-cell transplantation (SCT) in patients with chemorefractory non-Hodgkin's lymphoma. <i>Bone Marrow Transplantation</i> , <b>2008</b> , 41, 355-61	4.4	37
230	External validation and comparison of multiple prognostic scores in allogeneic hematopoietic stem cell transplantation. <i>Blood Advances</i> , <b>2019</b> , 3, 1881-1890	7.8	37
229	Prophylactic donor lymphocyte infusion after allogeneic stem cell transplantation in acute leukaemia - a matched pair analysis by the Acute Leukaemia Working Party of EBMT. <i>British Journal of Haematology</i> , <b>2019</b> , 184, 782-787	4.5	37
228	Post-remission strategies for the prevention of relapse following allogeneic hematopoietic cell transplantation for high-risk acute myeloid leukemia: expert review from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Bone Marrow Transplantation</i> , <b>2019</b> , 54, 519-530	4.4	36
227	Biosimilar G-CSF based mobilization of peripheral blood hematopoietic stem cells for autologous and allogeneic stem cell transplantation. <i>Theranostics</i> , <b>2014</b> , 4, 280-9	12.1	36

226	Allo-SCT for AML and MDS with treosulfan compared with BU-based regimens: reduced toxicity vs reduced intensity. <i>Bone Marrow Transplantation</i> , <b>2012</b> , 47, 1274-82	4.4	36
225	Factors associated with survival in patients with progressive disease following autologous transplant for lymphoma. <i>Bone Marrow Transplantation</i> , <b>2003</b> , 31, 565-9	4.4	36
224	Conditioning regimens for allogeneic hematopoietic stem cell transplants in acute myeloid leukemia. <i>Bone Marrow Transplantation</i> , <b>2017</b> , 52, 1504-1511	4.4	35
223	Autologous transplant vs oral chemotherapy and lenalidomide in newly diagnosed young myeloma patients: a pooled analysis. <i>Leukemia</i> , <b>2017</b> , 31, 1727-1734	10.7	35
222	Clinical practice recommendation on hematopoietic stem cell transplantation for acute myeloid leukemia patients with -internal tandem duplication: a position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Haematologica</i> , <b>2020</b> , 105, 1507-1516	6.6	34
221	Second reduced intensity conditioning allogeneic transplant as a rescue strategy for acute leukaemia patients who relapse after an initial RIC allogeneic transplantation: analysis of risk factors and treatment outcomes. <i>Bone Marrow Transplantation</i> , <b>2016</b> , 51, 186-93	4.4	33
220	Isolated Extramedullary Relapse of Acute Leukemia after Allogeneic Stem Cell Transplantation: Different Kinetics and Better Prognosis than Systemic Relapse. <i>Biology of Blood and Marrow Transplantation</i> , <b>2017</b> , 23, 1087-1094	4.7	33
219	Measurable residual disease at myeloablative allogeneic transplantation in adults with acute lymphoblastic leukemia: a retrospective registry study on 2780 patients from the acute leukemia working party of the EBMT. <i>Journal of Hematology and Oncology</i> , <b>2019</b> , 12, 108	22.4	33
218	Autologous stem cell transplantation for adult acute leukemia in 2015: time to rethink? Present status and future prospects. <i>Bone Marrow Transplantation</i> , <b>2015</b> , 50, 1495-502	4.4	33
217	Outcomes after use of two standard ablative regimens in patients with refractory acute myeloid leukaemia: a retrospective, multicentre, registry analysis. <i>Lancet Haematology</i> , <b>2015</b> , 2, e384-92	14.6	33
216	Peripheral blood stem cell graft compared to bone marrow after reduced intensity conditioning regimens for acute leukemia: a report from the ALWP of the EBMT. <i>Haematologica</i> , <b>2016</b> , 101, 256-62	6.6	33
215	Autologous transplant remains the preferred therapy for relapsed APL in CR2. <i>Bone Marrow Transplantation</i> , <b>2016</b> , 51, 1180-3	4.4	33
214	Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Patients Age >69 Years with Acute Myelogenous Leukemia: On Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , <b>2019</b> , 25, 1975-1983	4.7	32
213	Sorafenib improves survival of -mutated acute myeloid leukemia in relapse after allogeneic stem cell transplantation: a report of the EBMT Acute Leukemia Working Party. <i>Haematologica</i> , <b>2019</b> , 104, e398-e401	6.6	32
212	Acute GVHD prophylaxis plus ATLG after myeloablative allogeneic haemopoietic peripheral blood stem-cell transplantation from HLA-identical siblings in patients with acute myeloid leukaemia in remission: final results of quality of life and long-term outcome analysis of a phase 3 randomised study. <i>Lancet Haematology</i> , <b>2019</b> , 6, e89-e99	14.6	31
211	Conditioning intensity in middle-aged patients with AML in first CR: no advantage for myeloablative regimens irrespective of the risk group-an observational analysis by the Acute Leukemia Working Party of the EBMT. <i>Bone Marrow Transplantation</i> , <b>2015</b> , 50, 1063-8	4.4	31
210	Halofuginone has anti-proliferative effects in acute promyelocytic leukemia by modulating the transforming growth factor beta signaling pathway. <i>PLoS ONE</i> , <b>2011</b> , 6, e26713	3.7	31
209	Methods of ex vivo expansion of human cord blood cells: challenges, successes and clinical implications. <i>Expert Review of Hematology</i> , <b>2016</b> , 9, 297-314	2.8	30



208	Autologous stem cell transplantation for relapsed/refractory diffuse large B-cell lymphoma: efficacy in the rituximab era and comparison to first allogeneic transplants. A report from the EBMT Lymphoma Working Party. <i>Bone Marrow Transplantation</i> , <b>2016</b> , 51, 365-71	4.4	30
207	Comparable outcomes of haploidentical, 10/10 and 9/10 unrelated donor transplantation in adverse karyotype AML in first complete remission. <i>American Journal of Hematology</i> , <b>2018</b> , 93, 1236-1244	7.1	30
206	Halofuginone inhibits NF-kappaB and p38 MAPK in activated T cells. <i>Journal of Leukocyte Biology</i> , <b>2006</b> , 80, 399-406	6.5	30
205	Expanding transplant options to patients over 50 years. Improved outcome after reduced intensity conditioning mismatched-unrelated donor transplantation for patients with acute myeloid leukemia: a report from the Acute Leukemia Working Party of the EBMT. <i>Haematologica</i> , <b>2016</b> , 101, 773-80	6.6	30
204	Impact of Donor Epstein-Barr Virus Serostatus on the Incidence of Graft-Versus-Host Disease in Patients With Acute Leukemia After Hematopoietic Stem-Cell Transplantation: A Study From the Acute Leukemia and Infectious Diseases Working Parties of the European Society for Blood and Marrow Transplantation. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 2212-20	2.2	30
203	The impact of graft-versus-host disease prophylaxis in reduced-intensity conditioning allogeneic stem cell transplant in acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. <i>Haematologica</i> , <b>2015</b> , 100, 683-9	6.6	29
202	RIC versus MAC UCBT in adults with AML: A report from Eurocord, the ALWP and the CTIWP of the EBMT. <i>Oncotarget</i> , <b>2016</b> , 7, 43027-43038	3.3	29
201	Donor age determines outcome in acute leukemia patients over 40 undergoing haploidentical hematopoietic cell transplantation. <i>American Journal of Hematology</i> , <b>2018</b> , 93, 246-253	7.1	29
200	Intravenous Busulfan Compared with Treosulfan-Based Conditioning for Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia: A Study on Behalf of the Acute Leukemia Working Party of European Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , <b>2018</b> , 24, 751-757	4.7	28
199	Transplant Outcomes for Secondary Acute Myeloid Leukemia: Acute Leukemia Working Party of the European Society for Blood and Bone Marrow Transplantation Study. <i>Biology of Blood and Marrow Transplantation</i> , <b>2018</b> , 24, 1406-1414	4.7	28
198	Redefining and measuring transplant conditioning intensity in current era: a study in acute myeloid leukemia patients. <i>Bone Marrow Transplantation</i> , <b>2020</b> , 55, 1114-1125	4.4	28
197	Haploidentical vs. unrelated allogeneic stem cell transplantation for acute lymphoblastic leukemia in first complete remission: on behalf of the ALWP of the EBMT. <i>Leukemia</i> , <b>2020</b> , 34, 283-292	10.7	28
196	Sequential Intensified Conditioning Regimen Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Intermediate- or High-Risk Acute Myeloid Leukemia in Complete Remission: A Study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , <b>2017</b> , 23, 278-284	4.7	27
195	Killer cell immunoglobulin-like receptor ligand mismatching and outcome after haploidentical transplantation with post-transplant cyclophosphamide. <i>Leukemia</i> , <b>2019</b> , 33, 230-239	10.7	26
194	The Sphingosine-1-Phosphate Modulator FTY720 Targets Multiple Myeloma via the CXCR4/CXCL12 Pathway. <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 1733-1747	12.9	26
193	Allogeneic Stem Cell Transplantation for FLT3-Mutated Acute Myeloid Leukemia: T-Cell Depletion and Posttransplant Sorafenib Maintenance Improve Survival. A Retrospective Acute Leukemia Working Party-European Society for Blood and Marrow Transplant Study. <i>Clinical Hematology</i> , <b>2018</b> , 1, 50-71	1.8	26
192	Allogeneic stem cell transplantation in adult patients with acute myeloid leukaemia and 17p abnormalities in first complete remission: a study from the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT). <i>Journal of Hematology and Oncology</i> , <b>2017</b> , 10, 20	22.4	25
191	Long-term outcome after a treosulfan-based conditioning regimen for patients with acute myeloid leukemia: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Cancer</i> , <b>2017</b> , 123, 2671-2679	6.4	25

190	Autologous Hematopoietic Stem Cell Transplantation for Systemic Sclerosis: A Systematic Review and Meta-Analysis. <i>Biology of Blood and Marrow Transplantation</i> , <b>2018</b> , 24, 937-944	4.7	25
189	Mobilization of autologous and allogeneic peripheral blood stem cells for transplantation in haematological malignancies using biosimilar G-CSF. <i>Vox Sanguinis</i> , <b>2016</b> , 111, 178-86	3.1	25
188	Comparing i.v. BU dose intensity between two regimens (FB2 vs FB4) for allogeneic HCT for AML in CR1: a report from the Acute Leukemia Working Party of EBMT. <i>Bone Marrow Transplantation</i> , <b>2014</b> , 49, 1170-5	4.4	25
187	Impact of drug development on the use of stem cell transplantation: a report by the European Society for Blood and Marrow Transplantation (EBMT). <i>Bone Marrow Transplantation</i> , <b>2017</b> , 52, 191-196	4.4	25
186	Alloreactivity of umbilical cord blood mononuclear cells: specific hyporesponse to noninherited maternal antigens. <i>Human Immunology</i> , <b>2000</b> , 61, 548-54	2.3	25
185	Post-transplant cyclophosphamide after matched sibling, unrelated and haploidentical donor transplants in patients with acute myeloid leukemia: a comparative study of the ALWP EBMT. <i>Journal of Hematology and Oncology</i> , <b>2020</b> , 13, 46	22.4	24
184	Comparable results of autologous and allogeneic haematopoietic stem cell transplantation for adults with Philadelphia-positive acute lymphoblastic leukaemia in first complete molecular remission: An analysis by the Acute Leukemia Working Party of the EBMT. <i>European Journal of Cancer</i> , <b>2018</b> , 96, 73-81	7.5	24
183	Halofuginone inhibits multiple myeloma growth in vitro and in vivo and enhances cytotoxicity of conventional and novel agents. <i>British Journal of Haematology</i> , <b>2012</b> , 157, 718-31	4.5	24
182	Unrelated donor versus matched sibling donor in adults with acute myeloid leukemia in first relapse: an ALWP-EBMT study. <i>Journal of Hematology and Oncology</i> , <b>2016</b> , 9, 89	22.4	24
181	Anti- $\alpha$ 4 $\beta$ 7 integrin monoclonal antibody (vedolizumab) for the treatment of steroid-resistant severe intestinal acute graft-versus-host disease. <i>Bone Marrow Transplantation</i> , <b>2019</b> , 54, 987-993	4.4	24
180	Conditioning intensity in secondary AML with prior myelodysplastic syndrome/myeloproliferative disorders: an EBMT ALWP study. <i>Blood Advances</i> , <b>2018</b> , 2, 2127-2135	7.8	24
179	Allogeneic hematopoietic cell transplantation for primary refractory acute lymphoblastic leukemia: A report from the Acute Leukemia Working Party of the EBMT. <i>Cancer</i> , <b>2017</b> , 123, 1965-1970	6.4	23
178	Validation of the acute leukemia-EBMT score for prediction of mortality following allogeneic stem cell transplantation in a multi-center GITMO cohort. <i>American Journal of Hematology</i> , <b>2017</b> , 92, 429-434	7.1	23
177	Autologous stem cell transplantation for adult acute myelocytic leukemia in first remission-Better outcomes after busulfan and melphalan compared with busulfan and cyclophosphamide: A retrospective study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT). <i>Bone Marrow Transplantation</i> , <b>2017</b> , 52, 168-174	6.4	23
176	Long-term outcome and prognostic factors of second allogeneic hematopoietic stem cell transplant for acute leukemia in patients with a median follow-up of ?10 years. <i>Bone Marrow Transplantation</i> , <b>2015</b> , 50, 1508-12	4.4	23
175	Impact of Donor Type in Patients with AML Given Allogeneic Hematopoietic Cell Transplantation After Low-Dose TBI-Based Regimen. <i>Clinical Cancer Research</i> , <b>2018</b> , 24, 2794-2803	12.9	23
174	Impact of postremission consolidation chemotherapy on outcome after reduced-intensity conditioning allogeneic stem cell transplantation for patients with acute myeloid leukemia in first complete remission: a report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. <i>Cancer</i> , <b>2014</b> , 120, 855-63	6.4	23
173	Related donor transplants: has posttransplantation cyclophosphamide nullified the detrimental effect of HLA mismatch?. <i>Blood Advances</i> , <b>2018</b> , 2, 1180-1186	7.8	23

172	Allogeneic haematopoietic stem cell transplant in patients with lower risk myelodysplastic syndrome: a retrospective analysis on behalf of the Chronic Malignancy Working Party of the EBMT. <i>Bone Marrow Transplantation</i> , <b>2017</b> , 52, 209-215	4.4	22
171	Thiotepa-based conditioning versus total body irradiation as myeloablative conditioning prior to allogeneic stem cell transplantation for acute lymphoblastic leukemia: A matched-pair analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>American Journal of Hematology</i> , <b>2017</b> , 92, 997-1003	7.1	21
170	Comparing transplant outcomes in ALL patients after haploidentical with PTCy or matched unrelated donor transplantation. <i>Blood Advances</i> , <b>2020</b> , 4, 2073-2083	7.8	21
169	Head-to-head comparison of in-house produced CD19 CAR-T cell in ALL and NHL patients <b>2020</b> , 8,		21
168	Influence of pre-existing invasive aspergillosis on allo-HSCT outcome: a retrospective EBMT analysis by the Infectious Diseases and Acute Leukemia Working Parties. <i>Bone Marrow Transplantation</i> , <b>2016</b> , 51, 418-23	4.4	21
167	An Integrative Scoring System for Survival Prediction Following Umbilical Cord Blood Transplantation in Acute Leukemia. <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 6478-6486	12.9	21
166	Double umbilical cord blood transplant: more than a cell dose?. <i>Leukemia and Lymphoma</i> , <b>2010</b> , 51, 975-829		21
165	Regulatory abnormalities in the marrow of patients with myelodysplastic syndromes. <i>British Journal of Haematology</i> , <b>1989</b> , 73, 158-64	4.5	21
164	Trends in patient outcome over the past two decades following allogeneic stem cell transplantation for acute myeloid leukaemia: an ALWP/EBMT analysis. <i>Journal of Internal Medicine</i> , <b>2019</b> , 285, 407-418	10.8	21
163	Management of patients with acute leukemia during the COVID-19 outbreak: practical guidelines from the acute leukemia working party of the European Society for Blood and Marrow Transplantation. <i>Bone Marrow Transplantation</i> , <b>2021</b> , 56, 532-535	4.4	21
162	Neuronal conditioning medium and nerve growth factor induce neuronal differentiation of collagen-adherent progenitors derived from human umbilical cord blood. <i>Journal of Molecular Neuroscience</i> , <b>2007</b> , 32, 179-91	3.3	20
161	Characterization of HPSE gene single nucleotide polymorphisms in Jewish populations of Israel. <i>Acta Haematologica</i> , <b>2007</b> , 117, 57-64	2.7	20
160	Prediction of Hematopoietic Stem Cell Transplantation Related Mortality- Lessons Learned from the In-Silico Approach: A European Society for Blood and Marrow Transplantation Acute Leukemia Working Party Data Mining Study. <i>PLoS ONE</i> , <b>2016</b> , 11, e0150637	3.7	20
159	Alloreactivity: the Janus-face of hematopoietic stem cell transplantation. <i>Leukemia</i> , <b>2017</b> , 31, 1752-1759	10.7	19
158	Summary of Scientific and Statistical Methods, Study Endpoints and Definitions for Observational and Registry-Based Studies in Hematopoietic Cell Transplantation. <i>Clinical Hematology International</i> , <b>2020</b> , 2, 2-4	1.8	19
157	Risk factors and implications of oral mucositis in recipients of allogeneic hematopoietic stem cell transplantation. <i>European Journal of Haematology</i> , <b>2019</b> , 103, 402-409	3.8	18
156	Mobilized peripheral blood stem cells compared with bone marrow from HLA-identical siblings for reduced-intensity conditioning transplantation in acute myeloid leukemia in complete remission: a retrospective analysis from the Acute Leukemia Working Party of EBMT. <i>European Journal of Haematology</i> , <b>2012</b> , 89, 206-13	3.8	18
155	Expansion of megakaryocyte progenitors from human umbilical cord blood using a new two-step separation procedure. <i>British Journal of Haematology</i> , <b>1998</b> , 103, 639-50	4.5	18

154	Brentuximab vedotin in combination with or without donor lymphocyte infusion for patients with Hodgkin lymphoma after allogeneic stem cell transplantation. <i>Bone Marrow Transplantation</i> , <b>2016</b> , 51, 1313-1317	4.4	18
153	EBMT prospective observational study on allogeneic hematopoietic stem cell transplantation in T-prolymphocytic leukemia (T-PLL). <i>Bone Marrow Transplantation</i> , <b>2019</b> , 54, 1391-1398	4.4	17
152	Occurrence of graft-versus-host disease increases mortality after umbilical cord blood transplantation for acute myeloid leukaemia: a report from Eurocord and the ALWP of the EBMT. <i>Journal of Internal Medicine</i> , <b>2018</b> , 283, 178-189	10.8	17
151	Minimal residual disease status predicts outcome of acute myeloid leukaemia patients undergoing T-cell replete haploidentical transplantation. An analysis from the Acute Leukaemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT). <i>British Journal of Haematology</i> , <b>2018</b> , 183, 411-420	4.5	17
150	Prognostic Scoring Systems in Allogeneic Hematopoietic Stem Cell Transplantation: Where Do We Stand?. <i>Biology of Blood and Marrow Transplantation</i> , <b>2017</b> , 23, 1839-1846	4.7	17
149	Allogeneic hematopoietic SCT for adults AML using i.v. BU in the conditioning regimen: outcomes and risk factors for the occurrence of hepatic sinusoidal obstructive syndrome. <i>Bone Marrow Transplantation</i> , <b>2014</b> , 49, 628-33	4.4	17
148	Neurotherapeutic effect of cord blood derived CD45+ hematopoietic cells in mice after traumatic brain injury. <i>Journal of Neurotrauma</i> , <b>2014</b> , 31, 1405-16	5.4	17
147	Inverse correlation between HPSE gene single nucleotide polymorphisms and heparanase expression: possibility of multiple levels of heparanase regulation. <i>Journal of Leukocyte Biology</i> , <b>2009</b> , 86, 445-55	6.5	17
146	Prognostic factors for adult single cord blood transplantation among European and Japanese populations: the Eurocord/ALWP-EBMT and JSHCT/JDCHCT collaborative study. <i>Leukemia</i> , <b>2020</b> , 34, 128-137	10.7	17
145	Machine learning and artificial intelligence in haematology. <i>British Journal of Haematology</i> , <b>2021</b> , 192, 239-250	4.5	17
144	Matched unrelated donor allogeneic transplantation provides comparable long-term outcome to HLA-identical sibling transplantation in relapsed diffuse large B-cell lymphoma. <i>Bone Marrow Transplantation</i> , <b>2014</b> , 49, 671-8	4.4	16
143	Human umbilical cord blood stem cells: rational for use as a neuroprotectant in ischemic brain disease. <i>International Journal of Molecular Sciences</i> , <b>2010</b> , 11, 3513-28	6.3	16
142	Treatment of refractory autoimmune diseases with ablative immunotherapy. <i>Autoimmunity Reviews</i> , <b>2004</b> , 3, 21-9	13.6	16
141	Patterns of salivary microbiota injury and oral mucositis in recipients of allogeneic hematopoietic stem cell transplantation. <i>Blood Advances</i> , <b>2020</b> , 4, 2912-2917	7.8	16
140	Peripheral blood stem cell versus bone marrow transplantation: A perspective from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Experimental Hematology</i> , <b>2016</b> , 44, 567-73	3.1	16
139	The impact of individual comorbidities on non-relapse mortality following allogeneic hematopoietic stem cell transplantation. <i>Leukemia</i> , <b>2018</b> , 32, 1787-1794	10.7	16
138	Prognostic significance of recurring chromosomal abnormalities in transplanted patients with acute myeloid leukemia. <i>Leukemia</i> , <b>2019</b> , 33, 1944-1952	10.7	15
137	Unmanipulated haploidentical versus HLA-matched sibling allogeneic hematopoietic stem cell transplantation in relapsed/refractory acute myeloid leukemia: a retrospective study on behalf of the ALWP of the EBMT. <i>Bone Marrow Transplantation</i> , <b>2019</b> , 54, 1499-1510	4.4	15

136	The Role of Measurable Residual Disease (MRD) in Hematopoietic Stem Cell Transplantation for Hematological Malignancies Focusing on Acute Leukemia. <i>International Journal of Molecular Sciences</i> , <b>2019</b> , 20,	6.3	15
135	Effect of cord blood processing on transplantation outcomes after single myeloablative umbilical cord blood transplantation. <i>Biology of Blood and Marrow Transplantation</i> , <b>2015</b> , 21, 688-95	4.7	15
134	Distinct factors determine the kinetics of disease relapse in adults transplanted for acute myeloid leukaemia. <i>Journal of Internal Medicine</i> , <b>2018</b> , 283, 371-379	10.8	15
133	Fludarabine and treosulfan compared with other reduced-intensity conditioning regimens for allogeneic stem cell transplantation in patients with lymphoid malignancies. <i>Bone Marrow Transplantation</i> , <b>2015</b> , 50, 1526-35	4.4	14
132	Inferior outcome of allogeneic stem cell transplantation for secondary acute myeloid leukemia in first complete remission as compared to de novo acute myeloid leukemia. <i>Blood Cancer Journal</i> , <b>2020</b> , 10, 26	7	14
131	Prognostic pre-transplant factors in myelodysplastic syndromes primarily treated by high dose allogeneic hematopoietic stem cell transplantation: a retrospective study of the MDS subcommittee of the CMWP of the EBMT. <i>Annals of Hematology</i> , <b>2016</b> , 95, 1971-1978	3	14
130	Venous thromboembolism in hematopoietic stem cell transplant recipients. <i>Bone Marrow Transplantation</i> , <b>2016</b> , 51, 473-8	4.4	14
129	Trends in the use of hematopoietic stem cell transplantation for adults with acute lymphoblastic leukemia in Europe: a report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT). <i>Annals of Hematology</i> , <b>2019</b> , 98, 2389-2398	3	14
128	Single- or double-unit UCBT following RIC in adults with AL: a report from Eurocord, the ALWP and the CTIWP of the EBMT. <i>Journal of Hematology and Oncology</i> , <b>2017</b> , 10, 128	22.4	14
127	Cord blood stem cells for hematopoietic transplantation. <i>Stem Cell Reviews and Reports</i> , <b>2011</b> , 7, 425-336.4	33.6	14
126	Involved field radiation post autologous stem cell transplantation in lymphoma patients is associated with major haematological toxicities. <i>Medical Oncology</i> , <b>1998</b> , 15, 113-8	3.7	14
125	Timing of Post-Transplantation Cyclophosphamide Administration in Haploidentical Transplantation: A Comparative Study on Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , <b>2019</b> , 19, 103-110	4.7	14
124	Cyclophosphamide versus etoposide in combination with total body irradiation as conditioning regimen for adult patients with Ph-negative acute lymphoblastic leukemia undergoing allogeneic stem cell transplant: On behalf of the ALWP of the European Society for Blood and Marrow Transplantation. <i>American Journal of Hematology</i> , <b>2018</b> , 93, 778-785	7.1	13
123	Enhanced survival and neurite network formation of human umbilical cord blood neuronal progenitors in three-dimensional collagen constructs. <i>Journal of Molecular Neuroscience</i> , <b>2013</b> , 51, 249-633	6.3	13
122	Donor selection for a second allogeneic stem cell transplantation in AML patients relapsing after a first transplant: a study of the Acute Leukemia Working Party of EBMT. <i>Blood Cancer Journal</i> , <b>2019</b> , 9, 88	7	13
121	Nonmyeloablative stem cell transplantation: lessons from the first decade of clinical experience. <i>Psychophysiology</i> , <b>2004</b> , 3, 242-8		13
120	Individualized prediction of leukemia-free survival after autologous stem cell transplantation in acute myeloid leukemia. <i>Cancer</i> , <b>2019</b> , 125, 3566-3573	6.4	12
119	Identification of strong intron enhancer in the heparanase gene: effect of functional rs4693608 variant on HPSE enhancer activity in hematological and solid malignancies. <i>Oncogenesis</i> , <b>2018</b> , 7, 51	6.6	12

118	The expanding horizon of immunotherapy in the treatment of malignant disorders: allogeneic hematopoietic stem cell transplantation and beyond. <i>Annals of Medicine</i> , <b>2014</b> , 46, 384-96	1.5	12
117	Clinical implications of minimal residual disease monitoring for stem cell transplantation after reduced intensity and nonmyeloablative conditioning. <i>Acta Haematologica</i> , <b>2004</b> , 112, 93-104	2.7	12
116	Management of Adults and Children receiving CAR T-cell therapy: 2021 Best Practice Recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA). <i>Annals of Oncology</i> , <b>2021</b>	10.3	12
115	The impact of HLA-matching on reduced intensity conditioning regimen unrelated donor allogeneic stem cell transplantation for acute myeloid leukemia in patients above 50 years-a report from the EBMT acute leukemia working party. <i>Journal of Hematology and Oncology</i> , <b>2016</b> , 9, 65	22.4	12
114	Hematopoietic Cell Transplantation in the Treatment of Newly Diagnosed Adult Acute Myeloid Leukemia: An Evidence-Based Review from the American Society of Transplantation and Cellular Therapy. <i>Transplantation and Cellular Therapy</i> , <b>2021</b> , 27, 6-20		12
113	CAR T cells induce a complete response in refractory Burkitt Lymphoma. <i>Bone Marrow Transplantation</i> , <b>2018</b> , 53, 1583-1585	4.4	12
112	Novel strategies for improving hematopoietic reconstruction after allogeneic hematopoietic stem cell transplantation or intensive chemotherapy. <i>Expert Opinion on Biological Therapy</i> , <b>2017</b> , 17, 163-174	5.4	11
111	Refined graft-versus-host disease/relapse-free survival in transplant from HLA-identical related or unrelated donors in acute myeloid leukemia. <i>Bone Marrow Transplantation</i> , <b>2018</b> , 53, 1295-1303	4.4	11
110	Allogeneic stem cell transplantation benefits for patients $\geq 60$ years with acute myeloid leukemia and internal tandem duplication: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Haematologica</i> , <b>2018</b> , 103, 256-265	6.6	11
109	Biosimilar Filgrastim (Tevagrastim, XMO2) for Allogeneic Hematopoietic Stem Cell Mobilization and Transplantation in Patients with Acute Myelogenous Leukemia/Myelodysplastic Syndromes. <i>Biology of Blood and Marrow Transplantation</i> , <b>2016</b> , 22, 277-283	4.7	11
108	Modification of heparanase gene expression in response to conditioning and LPS treatment: strong correlation to rs4693608 SNP. <i>Journal of Leukocyte Biology</i> , <b>2014</b> , 95, 677-88	6.5	11
107	Successful human umbilical cord blood stem cell transplantation without conditioning in severe combined immune deficiency. <i>Bone Marrow Transplantation</i> , <b>1999</b> , 23, 405-8	4.4	11
106	Treatment with anti CD19 chimeric antigen receptor T cells after antibody-based immunotherapy in adults with acute lymphoblastic leukemia. <i>Current Research in Translational Medicine</i> , <b>2020</b> , 68, 17-22	3.7	11
105	Second allogeneic stem cell transplantation in patients with acute lymphoblastic leukaemia: a study on behalf of the Acute Leukaemia Working Party of the European Society for Blood and Marrow Transplantation. <i>British Journal of Haematology</i> , <b>2019</b> , 186, 767-776	4.5	10
104	Allogeneic stem cell transplantation in AML with t(6;9)(p23;q34);DEK-NUP214 shows a favourable outcome when performed in first complete remission. <i>British Journal of Haematology</i> , <b>2020</b> , 189, 920-925	4.5	10
103	AlloHSCT for inv(3)(q21;q26)/t(3;3)(q21;q26) AML: a report from the acute leukemia working party of the European society for blood and marrow transplantation. <i>Bone Marrow Transplantation</i> , <b>2018</b> , 53, 683-691	4.4	10
102	Baseline Renal Function and Albumin are Powerful Predictors for Allogeneic Transplantation-Related Mortality. <i>Biology of Blood and Marrow Transplantation</i> , <b>2018</b> , 24, 1685-1691	4.7	10
101	Comparable Long-Term Outcome after Allogeneic Stem Cell Transplantation from Sibling and Matched Unrelated Donors in Patients with Acute Myeloid Leukemia Older Than 50 Years: A Report on Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , <b>2019</b> , 25, 2251-2260	4.7	10

100	Interferon-gamma-induced neuronal differentiation of human umbilical cord blood-derived progenitors. <i>Leukemia</i> , <b>2009</b> , 23, 1790-800	10.7	10
99	Minimal residual disease post-bone marrow transplantation for hemato-oncological diseases. <i>Stem Cells</i> , <b>1996</b> , 14, 300-11	5.8	10
98	Current Status and Perspectives of Irradiation-Based Conditioning Regimens for Patients with Acute Leukemia Undergoing Hematopoietic Stem Cell Transplantation. <i>Clinical Hematology International</i> , <b>2019</b> , 1, 19-27	1.8	10
97	Bone marrow versus mobilized peripheral blood stem cell graft in T-cell-replete haploidentical transplantation in acute lymphoblastic leukemia. <i>Leukemia</i> , <b>2020</b> , 34, 2766-2775	10.7	10
96	Post-transplant cyclophosphamide versus anti-thymocyte globulin for graft-versus-host disease prevention in haploidentical transplantation for adult acute lymphoblastic leukemia. <i>Haematologica</i> , <b>2021</b> , 106, 1591-1598	6.6	10
95	Measurable residual disease (MRD) testing for acute leukemia in EBMT transplant centers: a survey on behalf of the ALWP of the EBMT. <i>Bone Marrow Transplantation</i> , <b>2021</b> , 56, 218-224	4.4	10
94	Remission of acute myeloid leukemia with t(8;21) following CD19 CAR T-cells. <i>Leukemia</i> , <b>2020</b> , 34, 1939-1942	10.7	9
93	Leukemia relapse following unmanipulated haploidentical transplantation: a risk factor analysis on behalf of the ALWP of the EBMT. <i>Journal of Hematology and Oncology</i> , <b>2019</b> , 12, 68	22.4	9
92	Induction of oral tolerance in bone marrow transplantation recipients suppresses graft-versus-host disease in a semiallogeneic mouse model. <i>Bone Marrow Transplantation</i> , <b>2003</b> , 32, 363-9	4.4	9
91	Fecal Microbiota Transplantation for Treatment of Acute Graft-Host Disease. <i>Clinical Hematology International</i> , <b>2019</b> , 1, 28-35	1.8	9
90	Evaluation of Trends and Prognosis Over Time in Patients with AML Relapsing After Allogeneic Hematopoietic Cell Transplant Reveals Improved Survival for Young Patients in Recent Years. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 6475-6482	12.9	9
89	Outcome of haploidentical versus matched sibling donors in hematopoietic stem cell transplantation for adult patients with acute lymphoblastic leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Journal of Hematology and Oncology</i> , <b>2021</b> , 14, 53	22.4	9
88	The combination of cyclosporine and mycophenolate mofetil is less effective than cyclosporine and methotrexate in the prevention of acute graft-versus host disease after stem-cell transplantation from unrelated donors. <i>American Journal of Hematology</i> , <b>2017</b> , 92, 259-268	7.1	8
87	Haploidentical stem cell transplantation (HaploSCT) for patients with acute leukemia-an update on behalf of the ALWP of the EBMT. <i>Bone Marrow Transplantation</i> , <b>2019</b> , 54, 713-718	4.4	8
86	G-CSF-primed BM for allogeneic SCT: revisited. <i>Bone Marrow Transplantation</i> , <b>2015</b> , 50, 892-8	4.4	8
85	Adults requiring cord blood transplants but have insufficient cell doses from a single cord blood unit can receive two units with successful engraftment kinetics similar to those of children receiving a single unit. <i>Leukemia and Lymphoma</i> , <b>2011</b> , 52, 635-41	1.9	8
84	Outcome after allogeneic transplantation for adult acute myeloid leukemia patients exhibiting isolated or associated trisomy 8 chromosomal abnormality: a survey on behalf of the ALWP of the EBMT. <i>Bone Marrow Transplantation</i> , <b>2009</b> , 44, 589-94	4.4	8
83	What is the outcome in patients with acute leukaemia who survive severe acute graft-versus-host disease?. <i>Journal of Internal Medicine</i> , <b>2018</b> , 283, 166-177	10.8	7

82	Total leucoderma: a rare manifestation of cutaneous chronic graft-versus-host disease. <i>British Journal of Dermatology</i> , <b>1996</b> , 134, 780-783	4	7
81	Natural killer cell alloreactivity in HLA-haploidentical hematopoietic transplantation: a study on behalf of the CTIWP of the EBMT. <i>Bone Marrow Transplantation</i> , <b>2021</b> , 56, 1900-1907	4.4	7
80	Hematopoietic stem cell transplantation for adults with relapsed acute promyelocytic leukemia in second complete remission. <i>Bone Marrow Transplantation</i> , <b>2021</b> , 56, 1272-1280	4.4	7
79	Post-transplantation cyclophosphamide versus antithymocyte globulin in patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation from HLA-identical sibling donors: A retrospective analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Cancer</i> , <b>2021</b> , 127, 209-218	6.4	7
78	The gastrointestinal tract: properties and role in allogeneic hematopoietic stem cell transplantation. <i>Expert Review of Hematology</i> , <b>2017</b> , 10, 315-326	2.8	6
77	LDH and renal function are prognostic factors for long-term outcomes of multiple myeloma patients undergoing allogeneic hematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , <b>2020</b> , 55, 1736-1743	4.4	6
76	Prognostic impact of progression to induction chemotherapy and prior paclitaxel therapy in patients with germ cell tumors receiving salvage high-dose chemotherapy in the last 10 years: a study of the European Society for Blood and Marrow Transplantation Solid Tumors Working Party. <i>Bone Marrow Transplantation</i> , <b>2016</b> , 51, 384-90	4.4	6
75	The mTOR inhibitor everolimus overcomes CXCR4-mediated resistance to histone deacetylase inhibitor panobinostat through inhibition of p21 and mitotic regulators. <i>Biochemical Pharmacology</i> , <b>2019</b> , 168, 412-428	6	6
74	Unrelated and related cord blood banking and hematopoietic graft engineering. <i>Cell and Tissue Banking</i> , <b>2003</b> , 4, 29-35	2.2	6
73	Effect of the combination of pegylated liposomal doxorubicin and bortezomib on time to progression (TTP) and overall survival of patients with relapsed/refractory multiple myeloma compared with bortezomib alone. <i>Journal of Clinical Oncology</i> , <b>2007</b> , 25, 8002-8002	2.2	6
72	Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in haematopoietic stem cell transplantation recipients. <i>British Journal of Haematology</i> , <b>2021</b> ,	4.5	6
71	Blocking of Transient Receptor Potential Vanilloid 1 (TRPV1) promotes terminal mitophagy in multiple myeloma, disturbing calcium homeostasis and targeting ubiquitin pathway and bortezomib-induced unfolded protein response. <i>Journal of Hematology and Oncology</i> , <b>2020</b> , 13, 158	22.4	6
70	Immune imitation of tumor progression after anti-CD19 chimeric antigen receptor T cells treatment in aggressive B-cell lymphoma. <i>Bone Marrow Transplantation</i> , <b>2021</b> , 56, 1134-1143	4.4	6
69	Total leucoderma: a rare manifestation of cutaneous chronic graft-versus-host disease. <i>British Journal of Dermatology</i> , <b>1996</b> , 134, 780-3	4	6
68	Apoptotic cells in allogeneic hematopoietic stem cell transplantations: "turning trash into gold". <i>Leukemia and Lymphoma</i> , <b>2012</b> , 53, 2130-5	1.9	5
67	Immunological effects of nilotinib prophylaxis after allogeneic stem cell transplantation in patients with advanced chronic myeloid leukemia or philadelphia chromosome-positive acute lymphoblastic leukemia. <i>Oncotarget</i> , <b>2017</b> , 8, 418-429	3.3	5
66	Development and validation of a disease risk stratification system for patients with haematological malignancies: a retrospective cohort study of the European Society for Blood and Marrow Transplantation registry. <i>Lancet Haematology</i> , <b>2021</b> , 8, e205-e215	14.6	5
65	EFFICACY AND SAFETY IN HIGH-RISK RELAPSED OR REFRACTORY INDOLENT FOLLICULAR LYMPHOMA PATIENTS TREATED WITH COPANLISIB. <i>Hematological Oncology</i> , <b>2019</b> , 37, 387-389	1.3	5



64	Allogeneic hematopoietic stem cell transplantation with fludarabine, busulfan, and thiotepa conditioning is associated with favorable outcomes in myelofibrosis. <i>Bone Marrow Transplantation</i> , <b>2020</b> , 55, 147-156	4.4	5
63	Second- and third-generation tyrosine kinase inhibitors for Philadelphia-positive adult acute lymphoblastic leukemia relapsing post allogeneic stem cell transplantation-a registry study on behalf of the EBMT Acute Leukemia Working Party. <i>Bone Marrow Transplantation</i> , <b>2021</b> , 56, 1190-1199	4.4	5
62	Gender disparities in the functional significance of anemia among apparently healthy adults. <i>European Journal of Haematology</i> , <b>2017</b> , 98, 435-442	3.8	4
61	Impact of detectable measurable residual disease on umbilical cord blood transplantation. <i>American Journal of Hematology</i> , <b>2020</b> , 95, 1057-1065	7.1	4
60	From patient centered risk factors to comprehensive prognostic models: a suggested framework for outcome prediction in umbilical cord blood transplantation. <i>Stem Cell Investigation</i> , <b>2017</b> , 4, 39	5.1	4
59	COPANLISIB IN PATIENTS WITH RELAPSED OR REFRACTORY INDOLENT B-CELL LYMPHOMA (CHRONOS-1). <i>Hematological Oncology</i> , <b>2017</b> , 35, 119-120	1.3	4
58	Repeated Courses of Orally Administered Fecal Microbiota Transplantation for the Treatment of Steroid Resistant and Steroid Dependent Intestinal Acute Graft Vs. Host Disease: A Pilot Study (NCT 03214289). <i>Blood</i> , <b>2018</b> , 132, 2121-2121	2.2	4
57	The impact of anti-thymocyte globulin on the outcomes of Patients with AML with or without measurable residual disease at the time of allogeneic hematopoietic cell transplantation. <i>Leukemia</i> , <b>2020</b> , 34, 1144-1153	10.7	4
56	FLAMSA-Based Reduced-Intensity Conditioning versus Myeloablative Conditioning in Younger Patients with Relapsed/Refractory Acute Myeloid Leukemia with Active Disease at the Time of Allogeneic Stem Cell Transplantation: An Analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Blood</i> , <b>2020</b> , 136, 2165-2173	4.7	4
55	Post-transplant cyclophosphamide containing regimens after matched sibling, matched unrelated and haploidentical donor transplants in patients with acute lymphoblastic leukemia in first complete remission, a comparative study of the ALWP of the EBMT. <i>Journal of Hematology and Oncology</i> , <b>2021</b> , 14, 84	22.4	4
54	RITUXIMAB SC AND IV PLUS CHOP SHOW SIMILAR EFFICACY AND SAFETY IN THE RANDOMISED MABEASE STUDY IN FIRST-LINE DLBCL. <i>Hematological Oncology</i> , <b>2017</b> , 35, 185-186	1.3	3
53	Nilotinib in steroid-refractory cGVHD: prospective parallel evaluation of response, according to NIH criteria and exploratory response criteria (GITMO criteria). <i>Bone Marrow Transplantation</i> , <b>2020</b> , 55, 2077-2086	4.4	3
52	Acute Myeloid Leukemia in Adults <b>2019</b> , 507-521		3
51	Second allogeneic haematopoietic cell transplantation using HLA-matched unrelated versus T-cell replete haploidentical donor and survival in relapsed acute myeloid leukaemia. <i>British Journal of Haematology</i> , <b>2021</b> , 193, 592-601	4.5	3
50	Allogeneic hematopoietic stem cell transplantation for adult patients with t(4;11)(q21;q23) KMT2A/AFF1 B-cell precursor acute lymphoblastic leukemia in first complete remission: impact of pretransplant measurable residual disease (MRD) status. An analysis from the Acute Leukemia Working Party of the EBMT. <i>Leukemia</i> , <b>2021</b> , 35, 2232-2242	10.7	3
49	Point-of-care anti-CD19 CAR T-cells for treatment of relapsed and refractory aggressive B cell lymphoma.. <i>Transplantation and Cellular Therapy</i> , <b>2022</b> ,		3
48	Reply to Lack of association of the heparanase gene single-nucleotide polymorphism Arg307Lys with acute lymphoblastic leukemia in patients from Northern Ireland by Winter et al.. <i>Leukemia</i> , <b>2008</b> , 22, 1631-1631	10.7	2
47	The impact of GVHD on outcomes after adult single cord blood transplantation in European and Japanese populations. <i>Bone Marrow Transplantation</i> , <b>2021</b> ,	4.4	2

46	Weathering the storm: COVID-19 infection in patients with hematological malignancies. <i>Journal of Zhejiang University: Science B</i> , <b>2020</b> , 21, 921-939	4.5	2
45	Comparable outcomes of haploidentical transplant with TBF conditioning versus matched unrelated donor with fludarabine/busulfan conditioning for acute myeloid leukemia. <i>Bone Marrow Transplantation</i> , <b>2021</b> , 56, 622-634	4.4	2
44	Allogeneic stem cell transplant in patients with acute myeloid leukemia and karnofsky performance status score less than or equal to 80%: A study from the acute leukemia working party of the European Society for Blood and Marrow Transplantation (EBMT). <i>Cancer Medicine</i> , <b>2021</b> , 10, 23-33	4.8	2
43	Improved Outcomes of Haploidentical Hematopoietic Cell Transplantation with Total Body Irradiation-Based Myeloablative Conditioning in Acute Lymphoblastic Leukemia. <i>Transplantation and Cellular Therapy</i> , <b>2021</b> , 27, 171.e1-171.e8		2
42	Underdiagnosed veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) as a major cause of multi-organ failure in acute leukemia transplant patients: an analysis from the EBMT Acute Leukemia Working Party. <i>Bone Marrow Transplantation</i> , <b>2021</b> , 56, 917-927	4.4	2
41	Allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome using treosulfan based compared to other reduced-intensity or myeloablative conditioning regimens. A report of the chronic malignancies working party of the EBMT. <i>British Journal of Haematology</i> , <b>2021</b> , 185, 117-126	4.5	2
40	Risk stratification using FLT3 and NPM1 in acute myeloid leukemia patients autografted in first complete remission. <i>Bone Marrow Transplantation</i> , <b>2020</b> , 55, 2244-2253	4.4	1
39	Cytogenetic risk score maintains its prognostic significance in AML patients with detectable measurable residual disease undergoing transplantation in remission: On behalf of the acute leukemia working party of the European society for blood and marrow transplantation. <i>American Journal of Hematology</i> , <b>2022</b> , 93, 1127-1137	7.1	1
38	Decision-analytic modeling as a tool for selecting optimal therapy incorporating hematopoietic stem cell transplantation in patients with hematological malignancy. <i>Bone Marrow Transplantation</i> , <b>2020</b> , 55, 1220-1228	4.4	1
37	Reply to Winter et al.. <i>Leukemia</i> , <b>2008</b> , 22, 1632-1633	10.7	1
36	Measurable residual disease, FLT3-ITD mutation, and disease status have independent prognostic influence on outcome of allogeneic stem cell transplantation in NPM1-mutated acute myeloid leukemia.. <i>Cancer Medicine</i> , <b>2022</b> ,	4.8	1
35	Prediction of Allogeneic HSCT Related Mortality in Acute Leukemia: Exploring Boundaries of Prediction through Machine Learning Based Modeling. a Data Mining Study from the Acute Leukemia Working Party (ALWP) of the EBMT. <i>Blood</i> , <b>2014</b> , 124, 2568-2568	2.2	1
34	Mechanism of HPSE Gene SNPs Function: From Normal Processes to Inflammation, Cancerogenesis and Tumor Progression. <i>Advances in Experimental Medicine and Biology</i> , <b>2020</b> , 1221, 231-249	3.6	1
33	A Machine Learning Based Model to Predict Two-Year Leukemia Free Survival in Cord Blood Transplantation for Acute Leukemia - a Data Mining Study, on Behalf of Eurocord, Cord Blood Committee and the Acute Leukemia Working Party of the EBMT. <i>Blood</i> , <b>2015</b> , 126, 3211-3211	2.2	1
32	Postremission Consolidation by Autologous Hematopoietic Cell Transplantation (HCT) for Acute Myeloid Leukemia in First Complete Remission (CR) and Negative Implications for Subsequent Allogeneic HCT in Second CR: A Study by the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT). <i>Biology of Blood and Marrow Transplantation</i> , <b>2020</b> , 26, 859-864	4.7	1
31	Comparing outcomes of a second allogeneic hematopoietic cell transplant using HLA-matched unrelated versus T-cell replete haploidentical donors in relapsed acute lymphoblastic leukemia: a study of the Acute Leukemia Working Party of EBMT. <i>Bone Marrow Transplantation</i> , <b>2021</b> , 56, 2194-2202	4.4	1
30	Measurable residual disease status and outcome of transplant in acute myeloid leukemia in second complete remission: a study by the acute leukemia working party of the EBMT. <i>Blood Cancer Journal</i> , <b>2021</b> , 11, 88	7	1
29	Allogeneic stem cell transplantation for AML patients with RUNX1 mutation in first complete remission: a study on behalf of the acute leukemia working party of the EBMT. <i>Bone Marrow Transplantation</i> , <b>2021</b> , 56, 2445-2453	4.4	1

28	Repetitively Administered Low-Dose Donor Lymphocyte Infusion for Prevention of Relapse after Allogeneic Stem Cell Transplantation in Patients with High-Risk Acute Leukemia. <i>Cancers</i> , <b>2021</b> , 13,	6.6	1
27	Impact of patient: donor HLA disparity on reduced-intensity-conditioned allogeneic stem cell transplants from HLA mismatched unrelated donors for AML: from the ALWP of the EBMT. <i>Bone Marrow Transplantation</i> , <b>2021</b> , 56, 614-621	4.4	1
26	Comparison of mycophenolate mofetil and calcineurin inhibitor versus calcineurin inhibitor-based graft-versus-host-disease prophylaxis for matched unrelated donor transplant in acute myeloid leukemia. A study from the ALWP of the EBMT. <i>Bone Marrow Transplantation</i> , <b>2021</b> , 56, 1077-1085	4.4	1
25	Better leukemia-free survival with allogeneic than with autologous HCT in AML patients with isolated trisomy 8: a study from the ALWP of the EBMT. <i>Bone Marrow Transplantation</i> , <b>2021</b> , 56, 461-469	4.4	1
24	Metabolic syndrome and cardiovascular disease after haematopoietic cell transplantation (HCT) in adults: an EBMT cross-sectional non-interventional study. <i>Bone Marrow Transplantation</i> , <b>2021</b> , 56, 2820-2825	4.4	1
23	Encouraging Survival and High Rates of Toxicity: Allogeneic Hematopoietic Cell Transplantation after Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy in Aggressive Lymphoma Patients. <i>Blood</i> , <b>2021</b> , 138, 910-910	2.2	0
22	Prediction Of Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) Related Mortality in Acute Leukemia: Generation Of a Machine Learning-Based Model Using The Data Set of The Acute Leukemia Working Party (ALWP) Of The EBMT. <i>Blood</i> , <b>2013</b> , 122, 409-409	2.2	0
21	Prognostic factors for neutrophil engraftment after haploidentical cell transplantation with PT-Cy in patients with acute myeloid leukemia in complete remission, on behalf of the ALWP-EBMT. <i>Bone Marrow Transplantation</i> , <b>2021</b> , 56, 1842-1849	4.4	0
20	Complete Remission with Incomplete Blood Count Recovery Is a Strong Predictor of Nonrelapse Mortality in Acute Myeloid Leukemia Patients Undergoing Allogeneic Stem Cell Transplantation. <i>Acta Haematologica</i> , <b>2021</b> , 144, 613-619	2.7	0
19	High lactate dehydrogenase at time of admission for allogeneic hematopoietic transplantation associates to poor survival in acute myeloid leukemia and non-Hodgkin lymphoma. <i>Bone Marrow Transplantation</i> , <b>2021</b> , 56, 2690-2696	4.4	0
18	Allogeneic HCT for adults with B-cell precursor acute lymphoblastic leukemia harboring IKZF1 gene mutations. A study by the Acute Leukemia Working Party of the EBMT. <i>Bone Marrow Transplantation</i> , <b>2021</b> , 56, 1047-1055	4.4	0
17	Total body irradiation + fludarabine compared to busulfan + fludarabine as "reduced-toxicity conditioning" for patients with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation in first complete remission: a study by the Acute Leukemia Working Party of the EBMT. <i>Bone Marrow Transplantation</i> , <b>2021</b> , 56, 1842-1849	4.4	0
16	Comparison of long-term outcome for AML patients alive free of disease 2 years after allogeneic hematopoietic cell transplantation with umbilical cord blood versus unrelated donor: a study from the ALWP of the EBMT. <i>Bone Marrow Transplantation</i> , <b>2021</b> , 56, 2742-2748	4.4	0
15	Low Protein Z levels in patients with plasma cell neoplasms are inversely correlated with IL-6 levels. <i>Leukemia Research</i> , <b>2017</b> , 62, 104-107	2.7	
14	BASELINE CLINICAL AND PET-CT TUMOR BURDEN PARAMETERS DO NOT PREDICT OUTCOME OF RELAPSE/REFRACTORY AGGRESSIVE B CELL LYMPHOMA PATIENTS TREATED WITH ANTI-CD19 CAR T-CELLS. <i>Hematological Oncology</i> , <b>2019</b> , 37, 504-505	1.3	
13	SAFETY ANALYSIS OF PATIENTS WITH A MEDICAL HISTORY OF RESPIRATORY DISORDERS TREATED WITH COPANLISIB FROM THE CHRONOS-1 STUDY IN RELAPSED OR REFRACTORY INDOLENT B-CELL LYMPHOMA. <i>Hematological Oncology</i> , <b>2019</b> , 37, 389-390	1.3	
12	COPANLISIB TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY MARGINAL ZONE LYMPHOMA. <i>Hematological Oncology</i> , <b>2019</b> , 37, 399-400	1.3	
11	IMPROVED SURVIVAL OUTCOMES FOR PATIENTS WITH EXTRA-NODAL NK/T LYMPHOMA: DATA FROM 140 PATIENTS PROSPECTIVELY REGISTERED IN THE INTERNATIONAL T-CELL PROJECT. <i>Hematological Oncology</i> , <b>2017</b> , 35, 78-79	1.3	

10	Immunotherapy for B-cell lymphoma. <i>Leukemia and Lymphoma</i> , <b>2010</b> , 51, 7-9	1.9
9	Introduction: advances and promise in human umbilical cord blood. <i>Best Practice and Research in Clinical Haematology</i> , <b>2010</b> , 23, 169-70	4.2
8	Umbilical Cord Blood Cells for Cardiac Repair <b>2008</b> , 59-72	
7	PI-14. <i>Clinical Pharmacology and Therapeutics</i> , <b>2006</b> , 79, P10-P10	6.1
6	Personalized Risk-Profiling for Acute Leukemia Patients Undergoing Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation: A Study on Behalf of the Acute Leukemia Working Party of the EBMT. <i>Blood</i> , <b>2020</b> , 136, 24-25	2.2
5	Cord Blood Derived CD34+ and AC133+ Progenitor Cells Ex-Vivo Expanded in the Presence of Tetraethylenepentamine: Reproducibility among Cord Blood Units.. <i>Blood</i> , <b>2004</b> , 104, 405-405	2.2
4	Ibritumomab tiuxetan combined with high-dose chemotherapy and autologous stem-cell transplantation (SCT) in patients with chemo-refractory aggressive non-Hodgkin lymphoma. <i>Journal of Clinical Oncology</i> , <b>2006</b> , 24, 6538-6538	2.2
3	Pegylated Liposomal Doxorubicin (PLD) in Combination with Bortezomib (B) May Provide Therapeutic Advantage for High-Risk Multiple Myeloma Patients Relapsing within 12 Months of Stem Cell Transplant.. <i>Blood</i> , <b>2007</b> , 110, 2730-2730	2.2
2	Comorbidity-Associated Risk of Overall Mortality Following Hematopoietic Stem-Cell Transplantation Is Regimen-Dependent: A Study from the Acute Leukemia Working Party of the EBMT. <i>Blood</i> , <b>2018</b> , 132, 203-203	2.2
1	Reply: Letter to the Editor Regarding "Autologous Stem Cell Transplantation for Systemic Sclerosis: A Systematic Review and Meta-Analysis". <i>Biology of Blood and Marrow Transplantation</i> , <b>2019</b> , 25, e114-e115	4.7